Dementia

How your vision can predict dementia 12 years before it is diagnosed – new study

Retrieved on: 
Wednesday, April 10, 2024

Our latest study shows that a loss of visual sensitivity can predict dementia 12 years before it is diagnosed.

Key Points: 
  • Our latest study shows that a loss of visual sensitivity can predict dementia 12 years before it is diagnosed.
  • Our research was based on 8,623 healthy people in Norfolk, England, who were followed up for many years.
  • By the end of the study, 537 participants had developed dementia, so we could see what factors might have preceded this diagnosis.
  • People who would develop dementia were much slower to see this triangle on the screen than people who would remain without dementia.

Recognising faces

  • We have some evidence which suggests that people with dementia tend to process new people’s faces inefficiently.
  • In other words, they don’t follow the usual pattern of scanning the face of the person they are talking to.
  • So this early issue in not recognising people you have just met could be related to ineffective eye movement for new faces, rather than being a pure memory disorder.

Can eye movement improve memory?

  • Previous research on the matter is mixed, but some studies found that eye movement can improve memory.
  • In other studies, eye movements from left to right and right to left done quickly (two eye movements per second) were found to improve autobiographical memory (your life story).
  • Also, using deficits in eye movements as a diagnostic is not a regular feature, despite the possibilities in eye movement technology.


Eef Hogervorst receives funding from the Dunhill Medical Trust [email protected] receives funding from Road Safety Trust. He is affiliated with Applied Vision Association. Ahmet Begde does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
Wednesday, April 10, 2024

In 2023, Airdoc Technology significantly accelerated its commercialization,while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization,while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Retrieved on: 
Wednesday, April 10, 2024

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Key Points: 
  • Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
    On March 27, medical artificial intelligence company Airdoc Technology (2251.
  • In 2023, through our SaMDs and health risk assessment solutions, we serviced a total of 6.83 million cases and identified 31,459 significant positive cases.
  • In 2023, Airdoc Medical broadened its reach to include hospitals, grassroots medical institutions such as community clinics, and health examination centers.
  • In June 2023, Airdoc, in collaboration with Tsinghua University's Chang Gung Hospital, developed and validated a new deep learning-based neovascular segmentation model.

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Retrieved on: 
Tuesday, April 9, 2024

Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.

Key Points: 
  • Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.
  • “Prior to these latest developments, moderate to severe OSA patients on Medicare were relegated almost entirely to a lifetime of some form of CPAP—something most patients find undesirable.
  • Our CARE oral medical devices, on the other hand, can significantly improve and even resolve OSA in about 12 months, with no further intervention required in most cases,” said Kirk Huntsman, Vivos Chairman and Chief Executive Officer.
  • “We are very pleased the Centers for Medicare and Medicaid Services (CMS) recognizes and validates the benefits our FDA cleared devices can have on the lives of patients diagnosed with OSA.

Is Sundown Syndrome Taking Over Your Evenings? Michele Nealon, Psy.D. Shares Expert Tips to Manage the Symptoms

Retrieved on: 
Tuesday, April 9, 2024

Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.

Key Points: 
  • Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.
  • This syndrome's cause is not well understood, but we know it can take a toll on the individual and their caregivers.
  • Setting a schedule of regular exercise, a healthy diet, and quality sleep for you and the person you are taking care of is imperative.
  • Patience and empathy are key when trying to ease their agitation because it can worsen if they sense your frustration.

Creyos Health Announces Addition of Dementia Screening, Testing, and Care Planning to its Online Platform

Retrieved on: 
Tuesday, April 9, 2024

This protocol, now available in the Creyos platform, is the result of 30 years of rigorous research and scientific validation.

Key Points: 
  • This protocol, now available in the Creyos platform, is the result of 30 years of rigorous research and scientific validation.
  • It offers full spectrum cognitive care, from early detection of mild cognitive impairment, to testing for an accurate dementia diagnosis, followed by tailored care planning, and ongoing longitudinal monitoring.
  • Dementia testing includes four additional tasks and behavioral health questionnaires, aligned with DSM-5 diagnostic criteria for dementia.
  • “We started Creyos because we noticed a significant gap in how cognitive health was being addressed,” said Marc Lipton, Co-Founder and CEO of Creyos.

Mental Performance Is the #1 Factor for Healthy Aging, According to Life Extension Survey

Retrieved on: 
Tuesday, April 9, 2024

So what’s more important when it comes to healthy aging: brain or brawn?

Key Points: 
  • So what’s more important when it comes to healthy aging: brain or brawn?
  • †February 2024 survey of Life Extension customers.
  • According to Michael A. Smith, MD , Life Extension’s Director of Education, aging healthily goes beyond flexing strong muscles; it also depends on heart health and, yes, cognition.
  • “Physical health is a no-brainer when it comes to healthy aging, but many don’t realize that maintaining cognitive health and performance, including a healthy mood, is also crucial,” Dr. Smith said.

Clearday to Host a Solar Watch Event– the Event of the Decade occurs today. A total Solar Eclipse is ready to travel from Texas to Maine.

Retrieved on: 
Monday, April 8, 2024

San Antonio, TX, April 08, 2024 (GLOBE NEWSWIRE) -- Clearday (OTCQX CLRD) is pleased to announce that Clearday Club Leon Valley is hosting a watch event for the Solar Eclipse.

Key Points: 
  • San Antonio, TX, April 08, 2024 (GLOBE NEWSWIRE) -- Clearday (OTCQX CLRD) is pleased to announce that Clearday Club Leon Valley is hosting a watch event for the Solar Eclipse.
  • The Clubs’ Solar Eclipse event will highlight engagement activities involving astronomy with a focus on the Stars, the Sun and the Moon!
  • We are planning the day’s menu around the sun as a theme – such as Sun Chips, raisins and Sunkissed products.
  • The Clearday Club is membership-based, offering an inspiring new kind of daytime destination for those with lifestyle-limiting chronic health conditions.

DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI

Retrieved on: 
Wednesday, April 3, 2024

The Company continues to expand its commercial initiatives in the U.S. and Canada for its CERVAI™ Brain Health AI Platform, which includes the BRAIN AGE® estimation solution, with world-class clinicians and hospital facilities such as the University of Miami Comprehensive Center for Brain Health, and in Canada’s leading research hospitals, such as Hamilton Health Sciences and St. Joe’s Healthcare Hamilton.

Key Points: 
  • The Company continues to expand its commercial initiatives in the U.S. and Canada for its CERVAI™ Brain Health AI Platform, which includes the BRAIN AGE® estimation solution, with world-class clinicians and hospital facilities such as the University of Miami Comprehensive Center for Brain Health, and in Canada’s leading research hospitals, such as Hamilton Health Sciences and St. Joe’s Healthcare Hamilton.
  • CERVAI™ Brain Health AI Platform is a world-first consumer brain health and wellness AI solution that estimates BRAIN AGE® and provides a brain health score.
  • Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a BRAIN AGE® Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues.
  • Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.